Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators

Medvi is not a drug company; instead, it operates as a customer acquisition model built on others’ regulated infrastructure. The New York Times published a profile of the company Medvi earlier this month, celebrating it as an example of what AI could help a single person do: build a telehealth company its founder projects will be worth $1.8 billion this year despite a closing loophole for telehealth companies selling compounded versions of popular metabolic drugs based on Lilly’s tirzepatide or Novo Nordisk’s semaglutide. Six weeks earlier, however, the FDA sent Medvi a warning letter for misbranding violations. And last May,…

Source: Drug Discovery & Development